IPCA Laboratories Limited has approved a Scheme of Amalgamation of Krebs Biochemicals & Industries Ltd. into IPCA Laboratories, with an appointed date of April 1, 2026. The board passed the resolution at its meeting held on June 26, 2026.
IPCA Laboratories reported a standalone audited total income of Rs 7,431 Crore for the financial year ended March 31, 2026. Krebs Biochemicals reported an audited total income of Rs 26 Crore for the same period, primarily from conversion charges received from IPCA Laboratories. Both entities are engaged in the manufacturing and marketing of pharmaceuticals.
As consideration, IPCA Laboratories will issue 7 fully paid-up equity shares of Re. 1 each for every 200 fully paid-up equity shares of Rs 10 each held in Krebs Biochemicals. No cash consideration will be payable under the scheme.
The amalgamation is expected to provide operational synergies and cost optimization through consolidation. IPCA Laboratories will gain access to fermentation-based Active Pharmaceutical Ingredients manufacturing capabilities that it currently does not possess. Krebs Biochemicals produces a fermentation-based API used in IPCA Laboratories' largest-selling formulation, with only a handful of manufacturers globally.
The scheme will enable IPCA Laboratories to research, develop, and commercialize new fermentation-based APIs while securing uninterrupted supply of key drug intermediates. The transaction is a related party transaction conducted at arm's length. Post-amalgamation, promoter shareholding will reduce to 44.66% from 44.72%, and public shareholding will rise to 55.34% from 55.28%.
Disclaimer: This article is based on company filings submitted to the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) and is for informational purposes only. It does not constitute investment advice or a recommendation. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.